TransMedics Group, Inc. $TMDX Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 15.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 132,972 shares of the company’s stock after purchasing an additional 17,637 shares during the quarter. Public Sector Pension Investment Board’s holdings in TransMedics Group were worth $14,919,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TMDX. Amalgamated Bank boosted its stake in shares of TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after buying an additional 80 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in TransMedics Group by 24.5% during the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after acquiring an additional 108 shares during the last quarter. State of Wyoming grew its holdings in TransMedics Group by 20.9% during the 3rd quarter. State of Wyoming now owns 683 shares of the company’s stock worth $77,000 after acquiring an additional 118 shares in the last quarter. Finally, TD Waterhouse Canada Inc. increased its position in shares of TransMedics Group by 26.5% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock worth $69,000 after purchasing an additional 126 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is owned by insiders.

TransMedics Group Trading Up 1.0%

Shares of NASDAQ TMDX opened at $129.84 on Friday. TransMedics Group, Inc. has a 12-month low of $62.07 and a 12-month high of $156.00. The company has a market cap of $4.44 billion, a price-to-earnings ratio of 52.57 and a beta of 2.06. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The stock’s 50 day simple moving average is $132.32 and its 200 day simple moving average is $125.42.

Analysts Set New Price Targets

TMDX has been the subject of a number of research reports. Morgan Stanley lifted their price target on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group raised their price objective on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Needham & Company LLC boosted their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.